Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema

<p>Interview with David W. Hutton, PhD, author of <a href= "https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2022.6142?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links"> Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema</a>. Hosted by Neil Bressler, MD.</p>